Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK-J1 lithium salt is an effective inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with an IC 50 of 60 nM for KDM6B.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | Inquiry | |
50 mg | 10-14 weeks | Inquiry | |
100 mg | 10-14 weeks | Inquiry |
Description | GSK-J1 lithium salt is an effective inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with an IC 50 of 60 nM for KDM6B. |
Targets&IC50 | KDM6B:60 nM |
In vitro | GSK-J1 is selective for H3K27 demethylases of the KDM6 subfamily and specifically binds to endogenous JMJD3. GSK-J1 inhibits TNF-α production by human primary macrophages in an H3K27-dependent manner [1]. GSK-J1 inhibits the demethylase activity of KDM5C with 8.5-fold increased potency than that of KDM5B at 1 mM α-ketoglutarate, with IC 50 of 11 μM and 94 μM, respectively [3]. |
Molecular Weight | 395.38 |
Formula | C22H22LiN5O2 |
CAS No. | 2309668-29-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK-J1 lithium salt 2309668-29-7 Chromatin/Epigenetic Histone Demethylase GSKJ1 lithium salt GSK-J1 lithium GSK-J-1 lithium salt GSK J1 lithium salt inhibitor inhibit